Related Experiment Video
Updated: Aug 7, 2026
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
IDN 5390: a new concept in taxane development
Giulia Taraboletti1, Gianluca Micheletti, Raffaella Giavazzi
1Department of Oncology, Mario Negri Institute for Pharmacological Research, Bergamo, Italy. taraboletti@marionegri.it
Abstract:
IDN 5390 is a seco-derivative cytostatic taxane. Originally selected for its ability to affect endothelial cell motility, the anti-angiogenic properties of IDN 5390 have been documented in experimental models, in vivo and in vitro. Preclinical studies indicate that, in vivo, oral IDN 5390 has a favorable bioavailability, is well tolerated and shows a significant anti-neoplastic activity on a panel of different tumor models, including paclitaxel-resistant tumors. According to its cytostatic rather than cytotoxic nature, frequent administrations of non-toxic doses have proven to be the optimal schedule for IDN 5390 treatment. Preliminary findings suggest the use of this compound in combination with conventional anti-neoplastic therapy. IDN 5390 can be considered the prototype of a new class of well-tolerated, orally available anti-angiogenic taxane derivatives with cytostatic properties.
Insights
IDN 5390, an oral anti-angiogenic taxane, demonstrates significant anti-neoplastic activity against various tumors, including resistant types. Its cytostatic nature allows for well-tolerated, frequent dosing, suggesting potential in combination cancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- IDN 5390 is a novel seco-derivative taxane with documented anti-angiogenic properties.
- Its mechanism involves affecting endothelial cell motility, impacting tumor growth.
- Preclinical evaluation is crucial for understanding its therapeutic potential.
Purpose of the Study:
- To evaluate the anti-neoplastic activity and tolerability of IDN 5390.
- To investigate the pharmacokinetic profile of orally administered IDN 5390.
- To explore the optimal dosing schedule for IDN 5390 based on its cytostatic nature.
Main Methods:
- In vivo and in vitro experimental models were utilized.
- A panel of different tumor models, including paclitaxel-resistant types, were used for efficacy testing.
- Bioavailability and tolerability studies were conducted following oral administration.
Main Results:
- Oral IDN 5390 exhibited favorable bioavailability and was well tolerated in preclinical studies.
- Significant anti-neoplastic activity was observed across various tumor models.
- Frequent administration of non-toxic doses proved optimal due to its cytostatic, rather than cytotoxic, effect.
Conclusions:
- IDN 5390 is a promising orally available, anti-angiogenic taxane derivative with cytostatic properties.
- It demonstrates efficacy against paclitaxel-resistant tumors, offering a potential new therapeutic option.
- Preliminary data suggest its utility in combination with conventional anti-neoplastic therapies.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules